Share ownership Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
733.04 ^USD	-1.20%		-7.97%	-5.03%

16/01	Where the Money's Moving
16/01	Bayer's Eylea Secures EU Approval for Retinal Vein Occlusion	MT

Share class: Regeneron Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	18,17,146	0	0	77.36 %
Stock B	1	13,57,07,536	10,63,83,352 ( 78.39 %)	2,82,00,000 ( 20.78 %)

Major shareholders: Regeneron Pharmaceuticals, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 8.761 %	90,48,269	8.761 %	6 984 M $
BlackRock Advisors LLC 6.382 %	65,91,583	6.382 %	5 088 M $
STATE STREET CORPORATION 4.542 %	46,91,223	4.542 %	3 621 M $
Dodge & Cox 4.406 %	45,50,845	4.406 %	3 513 M $
JPMorgan Investment Management, Inc. 3.944 %	40,73,609	3.944 %	3 144 M $
Geode Capital Management LLC 2.455 %	25,35,898	2.455 %	1 957 M $
Fiduciary Trust Company International 2.375 %	24,53,143	2.375 %	1 894 M $
BlackRock Life Ltd. 1.941 %	20,04,816	1.941 %	1 547 M $
Capital Research & Management Co. (World Investors) 1.935 %	19,98,366	1.935 %	1 542 M $
Loomis, Sayles & Co. LP 1.917 %	19,79,453	1.917 %	1 528 M $
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Leonard Schleifer 82.56 %	17,25,565	82.56 %	1 332 M $
George Yancopoulos 2.045 %	42,750	2.045 %	33 M $
Fineco Asset Management DAC 1.295 %	27,060	1.295 %	21 M $
BG Fund Management Luxembourg SA 0.2782 %	5,815	0.2782 %	4 M $
Ersel Asset Management SGR SpA 0.162 %	3,386	0.162 %	3 M $
Mercer Global Investments Europe Ltd. 0.1015 %	2,122	0.1015 %	2 M $
Eurizon Capital SA 0.0462 %	966	0.0462 %	745 626 $
Quaestio Capital Management SGR SpA 0.001483 %	31	0.001483 %	23 928 $
Mackenzie Investments Corp. (United States) 0.000383 %	8	0.000383 %	6 175 $

Breakdown by shareholder type

Institutional	68.32%
Other	11.35%
State Street Corp.	4.54%
Individuals	3.78%
Manulife Financial Corp.	0.37%
Sumitomo Mitsui Trust Group, Inc.	0.3%
Schweizerische Nationalbank	0.3%
The Bank of Nova Scotia	0.27%
Swedbank AB	0.2%
Governments	0.16%
Polar Capital Holdings Plc	0.15%
Zurich Insurance Group AG	0.15%
ING Groep NV	0.11%
SEI Investments Co.	0.08%
Skandinaviska Enskilda Banken AB	0.06%
Danske Bank A/S	0.05%
Banco Bilbao Vizcaya Argentaria SA	0.04%
Univest Financial Corp.	0.02%
Fifth Third Bancorp	0.01%
First Horizon Corp. (Tennessee)	0.01%
Ledyard Financial Group, Inc.	0.01%
Unknown	9.72%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	66.11%
United Kingdom	7.7%
Individuals	3.78%
Canada	3.06%
France	1.75%
Norway	1.28%
Japan	0.88%
Australia	0.72%
Switzerland	0.68%
Sweden	0.63%
Netherlands	0.56%
Luxembourg	0.52%
Germany	0.47%
Hong Kong	0.46%
South Korea	0.33%
Ireland	0.22%
Denmark	0.21%
Spain	0.19%
China	0.12%
Singapore	0.1%
Mexico	0.1%
Austria	0.09%
Finland	0.08%
Italy	0.06%
Belgium	0.04%
Czech Republic	0.03%
Puerto Rico	0.03%
Poland	0.01%
India	0.01%
New Zealand	0.01%
United Arab Emirates	0.01%
South Africa	0.01%
Taiwan	0.01%
Liechtenstein	0.01%
Slovenia	0.01%

Based on 1000 largest holdings

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (53.7%); - revenues from collaboration agreements (42.7%): collaboration with Sanofi (74.8% of revenues), Bayer (24.7%) and other (0.5%); - revenues from sales of technology licenses and subcontracted research services (3.6%). At the end of 2024, the group had a portfolio of approximately 40 products in clinical development.

Employees

15,222

Sector

Pharmaceuticals

Calendar

30/01 - Q4 2025 Earnings Release

More about the company